EyeGate Achieves 75% Enrollment in Pivotal Phase 3 Clinical Trial for Anterior Uveitis Triggering Milestone Payment
18 déc. 2017 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 18, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two platform...
Global Uveitis Treatment Market is Anticipated to Grow from an Estimated US$ 539.0 million in 2014 to US$ 822.5 million by 2020 by Persistence Market Research
28 avr. 2015 06h39 HE
|
Persistence Market Research
New York, April 28, 2015 (GLOBE NEWSWIRE) -- According to a new market report published by Persistence Market
Research "Global Market Study on Uveitis Treatment: Asia to
Witness fastest Growth by...